Archive for the ‘spain’ Category
Earlier this year, authors retracted a meeting abstract about a diabetes drug, following the revelation that the biotech that funded the trial committed misconduct.
The retraction was initiated by corresponding author Itamar Raz, at Hadassah Medical Center in Israel. The journal didn’t receive a response from any co-authors who were affiliated with the biotech company, Andromeda, so they were not included in the retraction process.
A few months after Hyperion Therapeutics acquired Andromeda’s diabetes drug DiaPep277, Hyperion announced it had evidence that some employees of Andromeda had “engaged in serious misconduct,” such as using un-blinded data and manipulating the analyses. Two relevant studies on the drug, designed to block the immune response that leads to type 1 diabetes, were retracted last year.
Here’s the retraction note for the abstract “Abstracts of the 50th Annual Meeting of the EASD, Vienna 2014. ‘Evaluation of DiaPep277® treatment in type 1 diabetes by integrated analysis,’” published in the May issue of the journal:
A group of astrophysicists has notched a pair of corrections for papers on galaxy clusters, thanks to an error that affected several figures in the papers, but not the overall conclusions.
The errors came in the catalog of “mock” galaxies that first author Fabio Zandanel, a postdoc at the University of Amsterdam, created to model features that are found in clusters of galaxies. Two mistakes canceled each other out “almost perfectly,” says Zandanel, making the changes that resulted from them subtle.
Zandanel explained the errors to us:
A 13th retraction has been published for Jesús Ángel Lemus, the Spanish veterinary researcher whose work colleagues have had trouble verifying.
This paper was pulled for similar reasons as his other retractions: After retrying the experiments in two independent labs, fellow authors were “unable to arrive to any sound conclusion about the validity of his analyses.”
Proceedings of the Royal Society B: Biological Sciences posted the notice September 16, three years after the paper received an expression of concern.
The retraction notice, signed by every co-author but Lemus, reads:
A paper that raised alarms by suggesting lizards were warming even faster than the planet has been retracted after the authors employed the wrong method to measure temperatures.
Some scientists thought that, because of the way lizards retain heat to regulate their cold-blooded bodies, they might be more sensitive to temperature changes. Well, not in this case. The paper has been retracted from Ecography because the scientists erred in calculating the “radiative conductance of the animal” — basically, how much heat it can get rid of — such that the “broad-scale” conclusions of the study are invalid.
The Journal of Biological Chemistry has posted withdrawal notices for six papers that had already been withdrawn, some more than a decade ago, in an effort to resolve “PubMed indexing problems.”
Each paper had been pulled by the author before it appeared in print, but still appeared online on the the journal’s website and in PubMed.
By our count, the journal has posted six notices so far, and said we should expect to see more in the future.
Kaoru Sakabe the Manager of Publication Issues at the American Society for Biochemistry and Molecular Biology, which publishes JBC, provided a statement on the new withdrawal notices: Read the rest of this entry »
Francisco Gómez Camacho has lost an introduction in The Journal of Markets and Morality of a 2005 issue “for improper use of published material without attribution, as well as a a chapter in a collection of 13 scholarly essays by Brill Publishers due to “serious citation issues.”
The introduction — to a translation of another scholars’ work, Luis de Molina’s Treatise on Money — is no longer in the online version of The Journal of Markets and Morality. On the cover page, and in the table of contents, of the treatise, references to the introduction are crossed out. Where it once was in the text — page 5 of the PDF of the treatise — is a short retraction notice:
Cell Press is looking into anonymous allegations that a pair of influential papers on gene activation in yeast may contain more than two dozen instances of image manipulation, according to a spokesperson for the journal.
The concerns raised on PubPeer have even sparked an investigation by an institution in Spain, which found no evidence to support the allegations. But not everyone agrees with that verdict.
The “worst moment of my scientific career:” Two bird migration articles brought down by analytical error
Evolutionary and conservation biologists in Spain are retracting two articles – one from the Journal of Avian Biology and the other from Ardeola – because they discovered a fatal flaw in their analysis.
The Journal of Avian Biology article, “Are European birds leaving traditional wintering grounds in the Mediterranean?” aimed to determine whether the abundance of passerines had decreased in recent decades, but failed to control for birds that may have gotten killed by hunters. Although it was published in January, we can only find an abstract from its acceptance by the journal in November 2014.
The paper, “Impact on Quality of Life of Using an Onlay Mesh to Prevent Incisional Hernia in Midline Laparotomy: A Randomized Clinical Trial,” came from a group at the Parc Tauli University Hospital, part of the Universitat Autònoma de Barcelona, in Spain.
By duplicating another paper, the authors (three of which appear to be listed on both papers) committed “a severe abuse of the scientific publishing system,” according to the retraction notice: Read the rest of this entry »
Several months after a drug company cancelled development of a potential diabetes cure because it found evidence that a biotech they had recently acquired had committed misconduct in studies of the drug, two retractions of relevant studies have appeared.
The research involves DiaPep277, which, as Josh Levy explained here in September, “would cause the immune system to stop attacking beta cells,” the cells in the pancreas that produce insulin. But Hyperion Therapeutics, which had acquired DiaPep277 developer Andromeda Biotech in June, announced in September that it had
uncovered evidence that certain employees of Andromeda Biotech, Ltd., which Hyperion acquired in June 2014, engaged in serious misconduct, including collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result.
The retractions are both of papers published in Diabetes Care in May 2014. Here’s the notice for “Treatment of Recent-Onset Type 1 Diabetic Patients With DiaPep277: Results of a Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial:” Read the rest of this entry »